Cancer Genetics beats by $0.10, beats on revenue

Cancer Genetics (CGIX): FQ3 EPS of -$0.61 beats by $0.10.

Revenue of $1.7M beats by $0.1M. (PR)

Comments (1)
  • russleehowe
    , contributor
    Comments (80) | Send Message
    Bought in early Sept at $9.60. Ran up over 100%. Dropped back after Oct 1st and now up again. Up 35% in 2 months. Not too bad. This is a winner.
    13 Nov 2013, 08:24 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs